
|Articles|March 24, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
PD-1 Inhibitors for Melanoma
Author(s)Jason J. Luke, MD
Jason J. Luke, MD, assistant professor of medicine, The University of Chicago, discusses PD-1 inhibitors for the treatment of patients with melanoma.
Advertisement
Jason J. Luke, MD, assistant professor of medicine, The University of Chicago, discusses PD-1 inhibitors for the treatment of patients with melanoma.
<<<
Articles in this issue
over 10 years ago
The Rationale for Immunotherapy in NSCLCover 10 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersover 10 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayover 10 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaover 10 years ago
Major Programs Under Way in Immuno-Oncologyover 10 years ago
Immunotherapy in GU CancersAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































